Spots Global Cancer Trial Database for er+
Every month we try and update this database with for er+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | NCT02619669 | Breast Cancer | TAK-228 Letrozole | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | NCT05080842 | Breast Cancer | AC682 | 18 Years - | Accutar Biotechnology Inc | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| ER Reactivation Therapy for Breast Cancer | NCT02188745 | Metastatic Brea... | 17B-estradiol Letrozole Anastrozole Exemestane | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT01216176 | Breast Cancer | Anastrozole AZD0530 (saraca... Placebo | 18 Years - | University of Miami | |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | NCT05774951 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane | 18 Years - 130 Years | AstraZeneca | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | NCT05952557 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane Abemaciclib | 18 Years - 130 Years | AstraZeneca | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | NCT01202591 | FGFR Inhibition... ER+ Breast Canc... | AZD4547 Exemestane Placebo Fulvestrant | 18 Years - 99 Years | AstraZeneca | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | NCT02374099 | Breast Neoplasm... | CC-486 Fulvestrant | 18 Years - | Celgene | |
| Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts | NCT02752893 | Breast Cancer | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer | NCT01814865 | Post-menopausal... | Abiraterone Ace... Prednisone Aromatase Inhib... | 18 Years - | British Columbia Cancer Agency | |
| Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts | NCT02752893 | Breast Cancer | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | NCT01441947 | Breast Cancer | Cabozantinib Fulvestrant | 18 Years - | Massachusetts General Hospital | |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | NCT01361945 | Breast Cancer Metastatic Brea... HER-2 Positive ... ER Positive Bre... | AUY922 | 18 Years - | Texas Tech University Health Sciences Center, El Paso | |
| Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | NCT01004744 | Invasive Breast... | Anastrozole | 21 Years - | Columbia University | |
| Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | NCT01004744 | Invasive Breast... | Anastrozole | 21 Years - | Columbia University | |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Breast Cancer | ARV-471 Anastrozole Surgical resect... | 18 Years - | Arvinas Inc. | |
| Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | NCT02374099 | Breast Neoplasm... | CC-486 Fulvestrant | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
